IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0087060.html
   My bibliography  Save this article

Efficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis

Author

Listed:
  • Huan Xia
  • Xiao-Juan Wang
  • Qiong Zhou
  • Huan-Zhong Shi
  • Zhao-Hui Tong

Abstract

Background: Talc pleurodesis has been widely used to control malignant pleural effusion; however, it is still not clear whether talc pleurodesis is more effective than other local therapies. We performed a meta-analysis to evaluate the efficacy and safety of talc pleurodesis in the management of malignant pleural effusion. Methods: PubMed, Embase, and Web of Science were searched for English-language studies of clinical controlled trials comparing talc pleurodesis with control therapies until August 8, 2013. Success rate and incidence of adverse events were evaluated. Relative risks were estimated using random- or fixed- effects model and statistical heterogeneity was assessed using I2 test. Results: Twenty trials involving 1,525 patients with malignant pleural effusion were included. The success rate of talc pleurodesis was significantly higher than that of control therapies (relative risk, 1.21; 95% confidence interval, 1.01–1.45; p = 0.035) with similar adverse events. In addition, thoracoscopic talc poudrage was more effective than bedside talc slurry (relative risk, 1.12; 95% confidence interval, 1.01–1.23; p = 0.026). Conclusions: The current evidences suggested the benefit for talc pleurodesis in the treatment of malignant pleural effusion. Talc pleurodesis, especially thoracoscopic talc poudrage pleurodesis, should be performed in patients with malignant pleural effusion, especially those with life-expectancy longer than one month.

Suggested Citation

  • Huan Xia & Xiao-Juan Wang & Qiong Zhou & Huan-Zhong Shi & Zhao-Hui Tong, 2014. "Efficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-9, January.
    • Handle: RePEc:plo:pone00:0087060
    DOI: 10.1371/journal.pone.0087060
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087060
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0087060&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0087060?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Yuan Su & Wei-Bing Yang & Shi Li & Zhi-Jian Ye & Huan-Zhong Shi & Qiong Zhou, 2012. "Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature," PLOS ONE, Public Library of Science, vol. 7(4), pages 1-1, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Irena Ilic & Slobodan Jankovic & Milena Ilic, 2016. "Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-15, August.
    2. Xing-Lin Chen & Ying-Hong Lei & Cun-Fei Liu & Qun-Fang Yang & Pei-Yuan Zuo & Cheng-Yun Liu & Chang-Zhong Chen & Yu-Wei Liu, 2013. "Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 8(6), pages 1-8, June.
    3. Fariba Ahmadizar & N Charlotte Onland-Moret & Anthonius de Boer & Geoffrey Liu & Anke H Maitland-van der Zee, 2015. "Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials," PLOS ONE, Public Library of Science, vol. 10(9), pages 1-27, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0087060. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.